Skip to main content


Fig. 1 | BMC Gastroenterology

Fig. 1

From: Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial

Fig. 1

CPP-1/sulindac downregulates PAs via dual MoA: CPP-1X decreases PA synthesis by blocking ODC1, and sulindac increases PA catabolism and export by upregulating transport genes (PPARγ and SAT). MoA, mechanism of action; ODC1, ornithine decarboxylase; PA, polyamine; PPAR, peroxisome proliferator activated receptor; SAT, sialic acid transport

Back to article page